Hepatocellular Carcinoma Clinical Trials in Beijing, None Selected
6 recruitingBeijing, None Selected, China
Showing 1–6 of 6 trials
Recruiting
Not Applicable
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular CarcinomaLenvatinibTranscatheter Arterial Chemoembolization+1 more
Sun Yat-sen University32 enrolled1 locationNCT06740370
Recruiting
Not Applicable
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular CarcinomaSystemic TherapyPortal Vein Tumor Thrombus
Sun Yat-sen University42 enrolled1 locationNCT06622031
Recruiting
Not Applicable
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Hepatocellular CarcinomaRecurrent TumorMicrowave Ablation+1 more
Sun Yat-sen University108 enrolled1 locationNCT06609876
Recruiting
Not Applicable
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
ChemotherapyAdvanced Hepatocellular CarcinomaAtezolizumab+1 more
Sun Yat-sen University27 enrolled1 locationNCT06609863
Recruiting
Not Applicable
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
AblationSystemic TherapyRecurrent Hepatocellular Carcinoma+2 more
Sun Yat-sen University116 enrolled1 locationNCT06609850
Recruiting
Not Applicable
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University60 enrolled1 locationNCT06550921